دورية أكاديمية
أعرض في EDS

Field Cancerization Therapies for the Management of Actinic Keratosis: An Updated Review.

التفاصيل البيبلوغرافية
العنوان: Field Cancerization Therapies for the Management of Actinic Keratosis: An Updated Review.
المؤلفون: Aggarwal I; Department of Dermatology, University of Illinois College of Medicine, 808 S. Wood St., Suite 380, Chicago, IL, 60612, USA., Puyana C; Department of Dermatology, University of Illinois College of Medicine, 808 S. Wood St., Suite 380, Chicago, IL, 60612, USA., Chandan N; Department of Dermatology, University of Illinois College of Medicine, 808 S. Wood St., Suite 380, Chicago, IL, 60612, USA., Jetter N; Department of Dermatology, University of Illinois College of Medicine, 808 S. Wood St., Suite 380, Chicago, IL, 60612, USA., Tsoukas M; Department of Dermatology, University of Illinois College of Medicine, 808 S. Wood St., Suite 380, Chicago, IL, 60612, USA. tsoukasm@uic.edu.
المصدر: American journal of clinical dermatology [Am J Clin Dermatol] 2024 May; Vol. 25 (3), pp. 391-405. Date of Electronic Publication: 2024 Feb 13.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100895290 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1888 (Electronic) Linking ISSN: 11750561 NLM ISO Abbreviation: Am J Clin Dermatol Subsets: MEDLINE
أسماء مطبوعة: Publication: Auckland : Adis, Springer International
Original Publication: Auckland ; Philadelphia : Adis International, c2000-
مواضيع طبية MeSH: Keratosis, Actinic*/therapy , Keratosis, Actinic*/drug therapy , Photochemotherapy*/methods , Photochemotherapy*/adverse effects , Skin Neoplasms*/prevention & control , Skin Neoplasms*/etiology , Skin Neoplasms*/therapy , Carcinoma, Squamous Cell*/prevention & control , Carcinoma, Squamous Cell*/etiology , Carcinoma, Squamous Cell*/therapy, Humans ; Cell Transformation, Neoplastic ; Administration, Cutaneous ; Treatment Outcome ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use ; Photosensitizing Agents/administration & dosage ; Photosensitizing Agents/adverse effects ; Photosensitizing Agents/therapeutic use ; Laser Therapy/methods
مستخلص: Field cancerization theory highlights that the skin surrounding actinic keratoses (AK) is also at increased risk for possible malignant transformation; thus, field-directed treatments may both reduce the risk of AK recurrence and potentially reduce the risk of development of cutaneous squamous cell carcinoma (cSCC). Photodynamic therapy (PDT) with either aminolevulinic acid (ALA) or methylaminolevulinate (MAL), as well as topical treatments such as 5-fluorouracil (5-FU), diclofenac gel, piroxicam, imiquimod, and ingenol mebutate, have all shown higher efficacy than vehicle treatments. PDT is widely recognized for its high efficacy; however, concerns for associated pain have driven new studies to begin using alternative illumination and pretreatment techniques, including lasers. Among topical treatments, a combination of 5-FU and salicylic acid (5-FU-SA) has shown to be the most effective but also causes the most adverse reactions. Tirbanibulin, a new topical agent approved for use in 2020, boasts a favorable safety profile in comparison with imiquimod, 5-FU, and diclofenac. Meanwhile, ingenol mebutate is no longer recommended for the treatment of AKs due to concerns for increased risk of cSCC development. Moving forward, an increasing number of studies push for standardization of outcome measures to better predict risk of future cSCC and use of more effective measures of cost to better guide patients. Here, we present an updated and comprehensive narrative review both confirming the efficacy of previously mentioned therapies as well as highlighting new approaches to PDT and discussing the use of lasers and novel topical treatments for treatment of AK.
(© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
References: Dirschka T, Ekanayake-Bohlig S, Dominicus R, Aschoff R, Herrera-Ceballos E, Botella-Estrada R, et al. A randomized, intraindividual, non-inferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the treatment of actinic keratosis. J Eur Acad Dermatol Venereol. 2019;33(2):288–97. (PMID: 3002254410.1111/jdv.15185)
Ulrich M, Reinhold U, Dominicus R, Aschoff R, Szeimies RM, Dirschka T. Red light photodynamic therapy with BF-200 ALA showed superior efficacy in the treatment of actinic keratosis on the extremities, trunk, and neck in a vehicle-controlled phase III study. J Am Acad Dermatol. 2021;85(6):1510–9. (PMID: 3374435010.1016/j.jaad.2021.03.031)
Campione E, Di Prete M, Di Raimondo C, Costanza G, Palumbo V, Garofalo V, et al. Topical treatment of actinic keratosis and metalloproteinase expression: a clinico-pathological retrospective study. Int J Mol Sci. 2022;23(19):11351. (PMID: 36232651956951610.3390/ijms231911351)
Cornejo CM, Jambusaria-Pahlajani A, Willenbrink TJ, Schmults CD, Arron ST, Ruiz ES. Field cancerization: treatment. J Am Acad Dermatol. 2020;83(3):719–30. (PMID: 3238766310.1016/j.jaad.2020.03.127)
Sotiriou E, Evangelou G, Papadavid E, Apalla Z, Vrani F, Vakirlis E, et al. Conventional vs daylight photodynamic therapy for patients with actinic keratosis on face and scalp: 12-month follow-up results of a randomized, intra-individual comparative analysis. J Eur Acad Dermatol Venereol. 2018;32(4):595–600. (PMID: 2897266310.1111/jdv.14613)
Government of Canada HC. PICATO (ingenol mebutate gel, 0.015% and 0.05%)—Product withdrawal in Canada due to potential increased risk of skin cancer - recalls, advisories and safety alerts—Canada.ca [Internet]. Government of Canada, Health Canada, Marketed health products. 2021. https://recalls-rappels.canada.ca/en/alert-recall/picato-ingenol-mebutate-gel-0015-and-005-product-withdrawal-canada-due-potential . Accessed 6 Jun 2023.
Piacquadio D, Houlihan A, Ferdon MB, Berg JE, Marcus SL. A randomized trial of broad area ala-pdt for field cancerization mitigation in high-risk patients. J Drugs Dermatol. 2020;19(5):452–8. (PMID: 3248463010.36849/JDD.2020.4930)
Jansen MHE, Kessels JPHM, Nelemans PJ, Kouloubis N, Arits AHMM, van Pelt HPA, et al. Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med. 2019;380(10):935–46. (PMID: 3085574310.1056/NEJMoa1811850)
Ahmady S, Jansen MHE, Nelemans PJ, Kessels JPHM, Arits AHMM, de Rooij MJM, et al. Risk of invasive cutaneous squamous cell carcinoma after different treatments for actinic keratosis. JAMA Dermatol. 2022;158(6):634–40. (PMID: 35475852904772710.1001/jamadermatol.2022.1034)
Arisi M, Zane C, Polonioli M, Tomasi C, Moggio E, Cozzi C, et al. Effects of MAL-PDT, ingenol mebutate and diclofenac plus hyaluronate gel monitored by high-frequency ultrasound and digital dermoscopy in actinic keratosis—a randomized trial. J Eur Acad Dermatol Venereol. 2020;34(6):1225–32. (PMID: 3179304110.1111/jdv.16123)
Mazzilli S, Garofalo V, Ventura A, Diluvio L, Milani M, Bianchi L, et al. Effects of topical 0.8% piroxicam and 50+ sunscreen filters on actinic keratosis in hypertensive patients treated with or without photosensitizing diuretic drugs: an observational cohort study. Clin Cosmet Investig Dermatol. 2018;12(11):485–90. (PMID: 10.2147/CCID.S178386)
Bobyr I, Campanati A, Giacchetti A, Offidani A. Fluorescent photodiagnostic evaluation of field cancerization treated with a medical device containing piroxicam 0.8% and sunscreen SPF 50+ for actinic keratosis. Photodermatol Photoimmunol Photomed. 2019;35(4):277–9. (PMID: 3069075810.1111/phpp.12452)
Agozzino M, Russo T, Franceschini C, Mazzilli S, Garofalo V, Campione E, et al. Effects of topical piroxicam and sun filters in actinic keratosis evolution and field cancerization: a two-center, assessor-blinded, clinical, confocal microscopy and dermoscopy evaluation trial. Curr Med Res Opin. 2019;35(10):1785–92. (PMID: 3114849010.1080/03007995.2019.1626227)
Befon A, Tzanetakou V, Panagiotopoulos A, Chasapi V, Antoniou C, Stratigos AJ. Imiquimod 3.75% for field-directed therapy of actinic keratosis: results of a prospective case-series study in Greece. Int J Dermatol. 2019;58(9):1040–4. (PMID: 30779341685034110.1111/ijd.14397)
Togsverd-Bo K, Halldin C, Sandberg C, Gonzalez H, Wennberg AM, Sørensen SS, et al. Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients: a randomized intraindividual controlled trial. British Journal of Dermatol. 2018;178(4):903–9. (PMID: 10.1111/bjd.15884)
Jetter N, Chandan N, Wang S, Tsoukas M. Field cancerization therapies for management of actinic keratosis: a narrative review. Am J Clin Dermatol. 2018;19(4):543–57. (PMID: 2958236910.1007/s40257-018-0348-7)
Wan MT, Lin JY. Current evidence and applications of photodynamic therapy in dermatology. Clin Cosmet Investig Dermatol. 2014;21(7):145–63.
Correia JH, Rodrigues JA, Pimenta S, Dong T, Yang Z. Photodynamic therapy review: principles, photosensitizers, applications, and future directions. Pharmaceutics. 2021;13(9):1332. (PMID: 34575408847072210.3390/pharmaceutics13091332)
Paragh G, Zeitouni NC. Two-step irradiance treatment can achieve excellent pain control during red light 5-aminolevulinic acid photodynamic therapy for actinic keratoses. Photomed Laser Surg. 2018;36(3):174–6. (PMID: 2922719910.1089/pho.2017.4351)
Silic K, Kammer M, Sator PG, Tanew A, Radakovic S. Efficacy of two different methods of cold air analgesia for pain relief in PDT of actinic keratoses of the head region—a randomized controlled comparison study. Photodiagnosis Photodyn Ther. 2022;40:103190. (PMID: 3633632310.1016/j.pdpdt.2022.103190)
Mordon S. Painless and efficient ALA-PDT and MAL-PDT of actinic keratosis can be achieved by drastically reducing the drug-light interval. Dermatologic Ther. 2020;33(3):e13423. (PMID: 10.1111/dth.13423)
Mordon S, Vignion-Dewalle AS, Abi-Rached H, Thecua E, Lecomte F, Vicentini C, et al. The conventional protocol vs. a protocol including illumination with a fabric-based biophotonic device (the Phosistos protocol) in photodynamic therapy for actinic keratosis: a randomized, controlled, noninferiority clinical study. Br J Dermatol. 2020;182(1):76–84. (PMID: 31021404)
Maire C, Vignion-Dewalle AS, Cartier H, Mordon S. Artificial white light photodynamic therapy for actinic keratosis: a study of 38 patients in private office practice. J Eur Acad Dermatol Venereol. 2020;34(4):e165–7. (PMID: 3177419810.1111/jdv.16112)
Salvio AG, Stringasci MD, Requena MB, de Oliveira ER, da Costa Medeiro MM, Bagnato VS. Field cancerization treatment: adjustments to an ALA red light photodynamic therapy protocol to improve pain tolerance. Photodiagnosis Photodyn Ther. 2021;35:102415. (PMID: 3419797010.1016/j.pdpdt.2021.102415)
Zaar O, Sjöholm Hylén A, Gillstedt M, Paoli J. A prospective, randomized, within-subject study of ALA-PDT for actinic keratoses using different irradiation regimes. Photodermatol Photoimmunol Photomed. 2018;34(5):338–42. (PMID: 2975330510.1111/phpp.12394)
Gholam P, Bosselmann I, Enk A, Fink C. Impact of red versus blue light on tolerability and efficacy of PDT: a randomized controlled trial. JDDG J Deutschen Dermatologischen Gesellschaft. 2018;16(6):711–7.
Gholam P, Bosselmann I, Enk AH, Dick J. Low irradiance compared with conventional photodynamic therapy in the treatment of actinic keratoses. Photodermatol Photoimmunol Photomed. 2019;35(2):110–5. (PMID: 3029002310.1111/phpp.12431)
Zhang G, Cao Z, Wang P, Zhu L, Zhang L, Zho Z, et al. Comparison of efficacy, adverse effects and costs between 20 % ALA-PDT and 10 % ALA-PDT for the treatment of actinic keratosis in Chinese patients. Photodiagnosis Photodyn Ther. 2020;31:101605. (PMID: 3178633410.1016/j.pdpdt.2019.101605)
Gan SD, Hsu SH, Chuang G, Konnikov N, Liang CA. Ablative fractional laser therapy for the treatment of actinic keratosis: a split-face study. J Am Acad Dermatol. 2016;74(2):387–9. (PMID: 2677578510.1016/j.jaad.2015.08.035)
Helsing P, Togsverd-Bo K, Veierød MB, Mørk G, Haedersdal M. Intensified fractional CO2 laser-assisted photodynamic therapy vs. laser alone for organ transplant recipients with multiple actinic keratoses and wart-like lesions: a randomized half-side comparative trial on dorsal hands. Br J Dermatol. 2013;169(5):1087–92. (PMID: 2385550310.1111/bjd.12507)
Paasch U, Said T. Treating field cancerization by ablative fractional laser and indoor daylight: assessment of efficacy and tolerability. J Drugs Dermatol. 2020;19(4):425–7. (PMID: 3227252110.36849/JDD.2020.4589)
Vrani F, Sotiriou E, Lazaridou E, Vakirlis E, Sideris N, Kirmanidou E, et al. Short incubation fractional CO2 laser-assisted photodynamic therapy vs conventional photodynamic therapy in field-cancerized skin: 12-month follow-up results of a randomized intraindividual comparison study. J Eur Acad Dermatol Venereol. 2019;33(1):79–83. (PMID: 2986944410.1111/jdv.15109)
Choi SH, Kim TH, Song KH. Efficacy of iontophoresis-assisted ablative fractional laser photodynamic therapy with short incubation time for the treatment of actinic keratosis: 12-month follow-up results of a prospective, randomised, comparative trial. Photodiagnosis Photodyn Ther. 2017;1(18):105–10. (PMID: 10.1016/j.pdpdt.2017.01.184)
Lonsdorf AS, Keller A, Hartmann J, Enk AH, Gholam P. Ablative fractional laser-assisted low-irradiance photodynamic therapy for treatment of actinic keratoses in organ transplant recipients: a prospective, randomized, intraindividual controlled trial. Acta Derm Venereol. 2022r;13(102):adv00694. (PMID: 10.2340/actadv.v102.1057)
Alexiades M. Randomized, controlled trial of fractional carbon dioxide laser resurfacing followed by ultrashort incubation aminolevulinic acid blue light photodynamic therapy for actinic keratosis. Dermatologic Surg. 2017;43(8):1053. (PMID: 10.1097/DSS.0000000000001117)
Togsverd-Bo K, Lei U, Erlendsson AM, Taudorf EH, Philipsen PA, Wulf HC, et al. Combination of ablative fractional laser and daylight-mediated photodynamic therapy for actinic keratosis in organ transplant recipients—a randomized controlled trial. Br J Dermatol. 2015;172(2):467–74. (PMID: 2497519910.1111/bjd.13222)
Wolf P. Ablative fractional laser-fortified daylight photodynamic therapy may be the patient’s preferred choice for the treatment of field cancerization. Br J Dermatol. 2019;180(4):697–8. (PMID: 3093333510.1111/bjd.17617)
Lindholm V, Pitkänen S, Schröder M, Hahtola S, Sahi H, Halme H, et al. Pulsed dye laser-mediated photodynamic therapy is less effective than conventional photodynamic therapy for actinic field cancerization: a randomized half-side comparative study. Acta Derm Venereol. 2021;101(2):adv00404. (PMID: 3349109310.2340/00015555-3754)
Galimberti GN. Daylight photodynamic therapy versus 5-fluorouracil for the treatment of actinic keratosis: a case series. Dermatol Ther (Heidelb). 2018;8(1):137–41. (PMID: 29322431582532410.1007/s13555-017-0219-9)
Garofalo V, Geraci F, Di-Prete M, Lanna C, Lozzi F, Cosio T, et al. Early clinical response to 5-fluorouracil 0.5% and salicylic acid 10% topical solution in the treatment of actinic keratoses of the head: an observational study. J Dermatolog Treat. 2022;33(5):2664–9. (PMID: 3543512810.1080/09546634.2022.2067817)
Stockfleth E, Bégeault N, Delarue A. Intensity of local skin reactions during 5-fluorouracil treatment related to the number of actinic keratosis lesions: a post hoc, exploratory analysis. Dermatol Ther (Heidelb). 2022;12(2):467–79. (PMID: 3495481110.1007/s13555-021-00668-9)
Cunningham TJ, Tabacchi M, Eliane JP, Tuchayi SM, Manivasagam S, Mirzaalian H, et al. Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. J Clin Invest. 2017;127(1):106–16. (PMID: 2786964910.1172/JCI89820)
Maytin EV, Anand S, Riha M, Lohser S, Tellez A, Ishak R, et al. 5-Fluorouracil enhances protoporphyrin ix accumulation and lesion clearance during photodynamic therapy of actinic keratoses: a mechanism-based clinical trial. Clin Cancer Res. 2018;24(13):3026–35. (PMID: 2959302810.1158/1078-0432.CCR-17-2020)
Campione E, Ventura A, Diluvio L, Mazzeo M, Mazzilli S, Garofalo V, et al. Current developments in pharmacotherapy for actinic keratosis. Expert Opin Pharmacother. 2018;19(15):1693–704. (PMID: 3022201110.1080/14656566.2018.1523896)
Babino G, Diluvio L, Bianchi L, Orlandi A, Di-Prete M, Chimenti S, et al. Long-term use of a new topical formulation containing piroxicam 0.8% and sunscreen: efficacy and tolerability on actinic keratosis. A proof of concept study. Curr Med Res Opin. 2016;32(8):1345–9. (PMID: 2704674410.1080/03007995.2016.1174678)
Lampley N, Rigo R, Schlesinger T, Rossi AM. Field therapy for actinic keratosis: a structured review of the literature on efficacy, cost, and adherence. Dermatol Surg. 2023;49(2):124–9. (PMID: 3672806110.1097/DSS.0000000000003677)
Nisticò S, Del-Duca E, Torchia V, Gliozzi M, Bottoni U, Muscoli C. Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis. Int J Immunopathol Pharmacol. 2018;32:2058.
Perino F, Fattori A, Piccerillo A, Bianchi L, Fargnoli MC, Frascione P, et al. Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care. Ital J Dermatol Venerol. 2022;157(2):164–72. (PMID: 34282872)
Neugebauer R, Su KA, Zhu Z, Sokil M, Chren MM, Friedman GD, et al. Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: a cohort study. J Am Acad Dermatol. 2019;80(4):998–1005. (PMID: 3045820810.1016/j.jaad.2018.11.024)
Emmerich VK, Cull D, Kelly KA, Feldman SR. Patient assessment of 5-fluorouracil and imiquimod for the treatment of actinic keratoses: a retrospective study of real-world effectiveness. J Dermatolog Treat. 2022;33(4):2075–8. (PMID: 3394730310.1080/09546634.2021.1917758)
Cortelazzi C, Odorici G, Castagnetti E, Pellacani G, Di-Nuzzo S. Comparative study of imiquimod 3.75% vs. photodynamic therapy for actinic keratosis of the scalp. Photodermatol Photoimmunol Photomed. 2021;37(5):404–9. (PMID: 3356643210.1111/phpp.12671)
https://www.facebook.com/Drugscom . FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp [Internet]. Drugs.com. 2023. https://www.drugs.com/newdrugs/fda-approves-klisyri-tirbanibulin-actinic-keratosis-face-scalp-5402.html . Accessed 5 Jun 2023.
Blauvelt A, Kempers S, Lain E, Schlesinger T, Tyring S, Forman S, et al. Phase 3 trials of tirbanibulin ointment for actinic keratosis. N Engl J Med. 2021;384(6):512–20. (PMID: 3356719110.1056/NEJMoa2024040)
Eisen DB, Asgari MM, Bennett DD, Connolly SM, Dellavalle RP, Freeman EE, et al. Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2021;85(4):e209–33. (PMID: 3382067710.1016/j.jaad.2021.02.082)
Number 4 SV 27. Tirbanibulin for the treatment of actinic keratosis: a review [Internet]. 2022. https://www.skintherapyletter.com/actinic-keratosis/tirbanibulin/ . Accessed 6 Jun 2023.
Dao DPD, Sahni VN, Sahni DR, Balogh EA, Grada A, Feldman SR. 1% Tirbanibulin ointment for the treatment of actinic keratoses. Ann Pharmacother. 2022;56(4):494–500. (PMID: 3430115310.1177/10600280211031329)
Kempers S, DuBois J, Forman S, Poon A, Cutler E, Wang H, et al. Tirbanibulin ointment 1% as a novel treatment for actinic keratosis: phase 1 and 2 results. J Drugs Dermatol. 2020;19(11):1093–100. (PMID: 3319675810.36849/JDD.2020.5576)
Steeb T, Wessely A, Petzold A, Brinker TJ, Schmitz L, Leiter U, et al. Evaluation of long-term clearance rates of interventions for actinic keratosis: a systematic review and network meta-analysis. JAMA Dermatol. 2021;157(9):1066–77. (PMID: 3434701510.1001/jamadermatol.2021.2779)
Reynolds KA, Schlessinger DI, Vasic J, Iyengar S, Qaseem Y, Behshad R, et al. Core outcome set for actinic keratosis clinical trials. JAMA Dermatol. 2020;156(3):326–33. (PMID: 3193999910.1001/jamadermatol.2019.4212)
Gollnick H, Dirschka T, Ostendorf R, Kerl H, Kunstfeld R. Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatol and Venereol. 2020;34(1):82–9. (PMID: 10.1111/jdv.15868)
Cheng B, Veerabagu S, Miller CJ, Sobanko JF, Shin TM, Higgins HW, et al. A comparison of invasive squamous cell carcinoma greater than 1 year after treatment with 5-fluorouracil, imiquimod, or photodynamic therapy with aminolevulinic acid. J Am Acad Dermatol. 2022;87(3):592–6. (PMID: 3566176010.1016/j.jaad.2022.05.051)
Acar A, Karaarslan I. Comparison of actinic keratosis and severity index with physician global assessment and total lesion count and the ability to predict skin cancer. Dermatol Pract Concept. 2022;12(1): e2022031. (PMID: 35223175882444010.5826/dpc.1201a31)
Schmitz L, von Dobbeler C, Gupta G, Gambichler T, Szeimies RM, Morton CA, et al. Photodynamic therapy leads to significant improvement of actinic keratosis area and severity index (AKASI). Photodiagnosis Photodyn Ther. 2018;21:66–70. (PMID: 2905112210.1016/j.pdpdt.2017.10.007)
Calzavara-Pinton P, Tanova N, Hamon P. Evaluation of the treatment costs and duration of topical treatments for multiple actinic keratosis based on the area of the cancerization field and not on the number of lesions. J Eur Acad Dermatol Venereol. 2019;33(2):312–7. (PMID: 3028878810.1111/jdv.15269)
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (Photosensitizing Agents)
تواريخ الأحداث: Date Created: 20240213 Date Completed: 20240505 Latest Revision: 20240508
رمز التحديث: 20240508
DOI: 10.1007/s40257-023-00839-8
PMID: 38351246
قاعدة البيانات: MEDLINE
الوصف
تدمد:1179-1888
DOI:10.1007/s40257-023-00839-8